The lawsuit specifically alleges that, from 2007 onward, Purdue significantly downplayed how addictive its opioids are and also overstated the benefits of opioids compared to other forms of pain management in order to increase its market share and profits. According to the complaint, since the 2007 consent judgment, Purdue “rather than reforming its opioid marketing to comply with the law … continued to mislead and obfuscate.”
Comments
Great plan.